GSK completes Novartis asset-swap deal, plans to return $4bn to shareholders
Pharmaceutical giant Glaxosmithkline (GSK) has finally completed its multibillion-dollar three-part asset-swap deal with Swiss peer Novartis, clearing the way for a big cash return for shareholders. The transaction, first announced in April 2014, saw GSK buy the bulk of Novartis' global vaccines bus
Read more